RCUS · Arcus Biosciences, Inc. · Investor Relations

HAYWARD, Calif. - Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer and inflammatory and autoimmune diseases, today announced the departure of its Chief Operations Officer Jennifer Jarrett, effective March 30, to pursue a CEO opportunity outside of Arcus. “Jen has been instrumental in the growth of Arcus from a nascent start-up with early research programs to a thriving biotech company with several programs in late-stage development and Phase 3 readouts over the next 12-24 months,” said Terry Rosen, Ph.D., chief executive officer of Arcus. “Arcus is in an exceptional position to maximize the opportunities within our portfolio, including our emerging immunology and inflammation development candidates, two of which are expected to enter the clinic over the coming year and casdatifan, a best-in-class HIF-2a inhibitor and potential future